



Pascal Biosciences names Carl Weissman acting President

VANCOUVER, BRITISH COLUMBIA, and SEATTLE, April 01, 2019 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) ("Pascal" or the "Company"), a drug discovery and development company, today announced that Carl Weissman has joined the company in the role of acting President. Weissman is a veteran of the biotechnology industry, with more than two decades of experience that spans investing, founding, and managing emerging biotech companies. Dr. Patrick Gray will continue in his role as CEO and director of the Company.

Weissman most recently served as a biotech investment advisor for Lightspeed Venture Partners, a venture capital firm focused on accelerating innovations and trends in enterprise and consumer sectors. Prior to that, he served as consulting CEO of OSS Healthcare, a joint venture of MPM Capital and Novartis Oncology. In 2003 he co-founded Accelerator Corporation (now known as Accelerator Life Science Partners), a joint investment vehicle backed by a syndicate of venture capital firms. From 2003 to 2014 he served as CEO and chairman at Accelerator as well as all 10 companies invested in and managed by Accelerator. Weissman was also previously a venture partner at MPM Capital. While at MPM, he served as President and CEO of Centagenetix, a human genetics company in Cambridge, MA. Prior to joining MPM, he spent six years at Prolinx, Inc., where he held a number of positions, culminating as the head of both Finance and Business Development.

"Carl's vast experience in directing and funding innovative companies in the biotechnology sector is invaluable and will serve Pascal well as we continue to advance our leading therapeutic product candidates and build shareholder value," said Dr. Patrick Gray, CEO of Pascal.

"Pascal Biosciences has an exciting and promising product pipeline that includes ground breaking molecules specifically for brain cancers and, more broadly, enhancing checkpoint inhibitors," said Weissman. "It's rewarding to be involved in helping to further advance these opportunities to a point where they may substantially improve patient outcomes."

About Pascal Biosciences Inc.

Pascal Biosciences is a biotechnology company focused on advancing innovative approaches for the treatment of cancer including cannabinoid-based therapeutics and targeted therapies. The company's leading portfolio comprises a small molecule therapeutic, PAS-403, that is advancing into clinical trials for the treatment of glioblastoma, and PAS-393, an immuno-stimulatory

cannabinoid to be used in combination with checkpoint inhibitor therapy. In addition, Pascal Biosciences is developing a B-cell targeted antibody for acute lymphoblastic leukemia. For more information, visit www.pascalbiosciences.com.

Investors:

invest@pascalbiosciences.com

Media Contact:

Julie Rathbun

info@pascalbiosciences.com

Tel: 206-769-9219

DISCLAIMER

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”